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Abstract  Choroidal  hemangioma  is  a  rare  congenital  ocular  tumor  that  can  present  as  either
circumscribed  or  diffuse.  Circumscribed  choroidal  hemangioma  (CCH)  typically  manifests  as  a
red-orange  mass  within  the  posterior  pole  and  appears  similar  to  other  ocular  conditions,  such
as choroidal  melanoma  and  choroidal  metastasis.  Proper  diagnosis  is  crucial  and  is  aided  by
the use  of  ancillary  testing.  CCH  itself  is  benign  but  can  cause  secondary  complications  such
as subretinal  ﬂuid  accumulation  and  subsequent  retinal  detachment.  If  these  conditions  should
arise, several  treatment  options  are  available.
© 2016  Published  by  Elsevier  España,  S.L.U.  on  behalf  of  Spanish  General  Council  of  Optometry.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Hemangioma  circunscrito  de  coroides:  informe  de  un  caso  y  revisión  de  la  literatura
Resumen  El  hemangioma  coroideo  es  un  raro  tumor  ocular  congénito  que  puede  presentarse
de manera  circunscrita  o  difusa.  El  hemangioma  circunscrito  de  coroides  (CCH)  se  maniﬁesta
típicamente  como  una  masa  rojizo-anaranjada  en  el  interior  del  polo  posterior,  y  parece  similar
a otras  situaciones  oculares,  tales  como  el  melanoma  coroideo  y  la  metástasis  coroidea.  El
diagnóstico  adecuado  es  esencial,  y  viene  asistido  por  el  uso  de  pruebas  complementarias.  El
CCH en  sí  mismo  es  benigno,  aunque  puede  originar  complicaciones  secundarias  tales  como  la
acumulación  de  ﬂuidos  sub-retinianos  y  el  subsiguiente  desprendimiento  de  retina.  En  caso  de
producirse  dichas  situaciones,  existen  diversas  opciones  de  tratamiento.
© 2016  Publicado  por  Elsevier  España,  S.L.U.  en  nombre  de  Spanish  General  Council  of  Optome-
try. Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Please  cite  this  article  in  press  as:  Berry  M,  Lucas  LJH.  Circumsc
review.  J  Optom.  (2016),  http://dx.doi.org/10.1016/j.optom.2
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Choroidal  hemangioma  is  a  benign  vascular  tumor.1,2 It
s  considered  a  congenital  condition  but  can  continue  to
evelop  into  early  adulthood.2,3 Choroidal  hemangiomas  are
lassiﬁed  into  two  subtypes,  circumscribed  and  diffuse,  a
istinction  made  based  on  the  extent  of  choroidal  involve-
ent.  Diffuse  choroidal  hemangiomas  involve  more  than  one
uadrant  of  the  choroid  and  are  typically  associated  with
ystemic  conditions  such  as  Sturge--Weber  syndrome.1--4 Cir-
umscribed  choroidal  hemangioma  (CCH)  typically  presents
s  a  unilateral  orange-red  choroidal  mass  without  corre-
ation  to  systemic  conditions.  CCH  may  appear  similar  to
ther  choroidal  tumors,  some  of  which  are  malignant,  such
s  choroidal  melanoma  and  choroidal  metastasis.2,3 For
his  reason,  it  is  important  to  be  able  to  differentiate
etween  these  lesions.  This  can  be  accomplished  by  employ-
ng  ancillary  testing  such  as  ultrasonography,  ﬂuorescein
ngiography  (FA),  indocyanine  green  angiography  (ICGA),
agnetic  resonance  imaging  (MRI),  and  optical  coher-
nce  tomography  (OCT).2,3 Once  the  diagnosis  has  been
ade,  referral  to  a  retinal  specialist  is  usually  warranted.
reatment  options  include  laser  photocoagulation,  ther-
otherapy,  radiotherapy,  photodynamic  therapy  (PDT),  and
nti-vascular  endothelial  growth  factor  (VEGF)  therapy.1,5--9
ase report
elevant  history
 49-year-old  Caucasian  male  presented  to  clinic  with  com-
laints  of  blurred  vision  at  distance  that  was  worse  in  his
eft  eye.  His  medical  history  included  hypertension,  hyper-
ipidemia,  sleep  apnea,  and  post-traumatic  stress  disorder.
is  ocular  history  was  unremarkable.
linical  ﬁndings
he  patient’s  best-corrected  visual  acuities  (BVA)  were
0/20  OD  and  20/100  OS,  and  he  consistently  missed  let-
ers  on  the  left  side  of  the  chart  with  his  left  eye.  Pupils
ere  equal,  round,  and  reactive  to  light  OU,  and  there  was
o  afferent  pupillary  defect.  Confrontation  ﬁelds  were  full,
nd  extra-ocular  muscles  had  full  range  of  motion.  Amsler
rid  was  unremarkable  OD  and  revealed  left-sided  metamor-
hopsia  OS.  Slit  lamp  examination  was  unremarkable  OU,
nd  intraocular  pressures  were  within  normal  limits.  Dilated
undus  exam  of  the  left  eye  (Fig.  1)  revealed  a  2DD  orange-
ed  elevated  lesion  superior  temporal  to  the  optic  nerve
ead  with  overlying  retinal  pigment  epithelium  change  and
igmentation.  An  associated  3--4  DD  central  serous  retinal
etachment  was  also  noted.  Several  ancillary  tests  were
erformed.  Ultrasonography  showed  a  2  mm  ×  8  mm  solid
horoidal  mass  on  B-scan  with  high  internal  reﬂectivity  on
-scan.  OCT  revealed  a  large  choroidal  mass  with  overlying
ubretinal  ﬂuid.  Fundus  photos  were  also  taken.
anagement/follow-upPlease  cite  this  article  in  press  as:  Berry  M,  Lucas  LJH.  Circumsc
review.  J  Optom.  (2016),  http://dx.doi.org/10.1016/j.optom.
he  patient  was  diagnosed  with  CCH  and  referred  to  a  reti-
al  specialist.  Fluorescein  angiography  was  performed,  and
t  showed  hyperﬂourescence  in  all  stages.  The  lesion  was
reated  with  argon  laser  photocoagulation  over  the  entire
p
t
3igure  1  Fundus  photo  shows  a  circumscribed  choroidal
emangioma  superior  temporal  to  the  optic  nerve  in  the  left
ye.
ass.  The  patient  was  seen  two  weeks  later,  and  BVA  was
0/50  OS.  Dilated  fundus  exam  revealed  an  improvement  in
ubretinal  ﬂuid,  but  a  serous  detachment  was  still  present.
A  was  repeated  as  well  as  another  session  of  argon  laser
hotocoagulation.
Over  the  next  15  years,  the  patient  was  seen  every  three
o  six  months  depending  on  the  status  of  the  condition.  After
hree  treatments  of  argon  laser  photocoagulation,  all  of  the
ubretinal  ﬂuid  resolved.  The  CCH  did  not  shrink  in  size.  Pig-
ent  later  developed  over  the  lesion.  BVA  remained  around
0/30  at  each  follow-up  visit.  The  subretinal  ﬂuid  eventu-
lly  returned  11  years  after  the  last  treatment  session,  but
t  did  not  affect  the  patient’s  vision.  Therefore,  observation
as  chosen  as  the  treatment  at  that  time.  No  changes  in
he  amount  of  subretinal  ﬂuid  or  BVA  have  been  noted  at
ny  follow-up  visits  since.
iterature review
ackground
CH  is  a  rare  vascular  tumor.1,3 It  is  considered  to  be  con-
enital  in  nature;  however,  it  often  does  not  cause  symptoms
ntil  the  fourth  to  sixth  decade  of  life.2,3 It  is  observed  more
requently  in  Caucasians  and  equally  between  the  sexes.
CH  is  a  very  uncommon  tumor  that  is  likely  to  go  undi-
gnosed  unless  the  patient  becomes  symptomatic.
Unlike  diffuse  choroidal  hemangiomas,  which  are  asso-
iated  with  phakomatoses  such  as  Sturge--Weber  syndrome,
CH  has  no  correlation  with  systemic  disease.3,4 CCH  is  com-
osed  of  dilated  choroidal  vessels  but  does  not  involve  the
horiocapillaris.  The  speciﬁc  cause  of  the  blood  vessel  mal-
ormation  is  unknown.  CCH  is  different  from  other  ‘‘true
emangiomas’’  in  that  it  does  not  show  cellular  prolifera-
ion.  In  other  words,  it  shows  slow  to  no  progression  in  size
ver  time.2,3ribed  choroidal  hemangioma:  A  case  report  and  literature
2015.12.006
CCH  presents  clinically  as  an  orange-red  mass  in  the
osterior  pole,  usually  within  one  to  three  disk  diame-
ers  of  the  macula.2--4 They  typically  range  in  size  from
 to  19  mm  in  diameter  and  1  to  8  mm  in  thickness.  The
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Circumscribed  choroidal  hemangioma  
mass  itself  is  not  pigmented  but  overlying  pigment  can
develop  over  time.  CCH  is  a  slowly  progressive  tumor.  It
can  appear  to  increase  in  size  secondary  to  subretinal  ﬂuid
accumulation.2,3
Signs  and  symptoms
Presenting  symptoms  can  range  from  no  symptoms  to  sig-
niﬁcant  vision  loss.  In  a  200-patient  study  by  Shields  et  al.,
the  most  common  symptom  was  blurred  vision  followed  by
a  loss  in  visual  ﬁeld.  Other  symptoms  can  include  metamor-
phopsia,  ﬂoaters,  ﬂashes  of  light,  and  rarely  ocular  pain.
Many  of  these  symptoms  are  caused  by  subretinal  ﬂuid  accu-
mulation.  This  occurs  secondary  to  a  breakdown  of  the
blood-retinal  barrier,  allowing  ﬂuid  leakage  that  leads  to  a
serous  retinal  detachment.3
Clinically,  signs  include  an  orange-red  dome-shaped
lesion  with  indistinct  borders.3 Rarely,  the  tumor  can  take  on
more  of  a  plateau  or  mushroom  shape,  which  increases  the
likelihood  of  misdiagnosis  of  a  more  serious  ocular  condi-
tion.  Other  associated  clinical  signs  can  include  dilated
episcleral  vessels,  neovascularization  of  the  iris,  drusen,
RPE  hyperplasia,  dilated  retinal  arteries  and  veins,  and
retinoschisis.2,3
Differential  diagnosis
Several  posterior  segment  lesions  can  resemble  CCH.
These  include  central  serous  chorioretinopathy,  choroidal
melanoma,  choroidal  metastasis,  posterior  nodular  scleritis,
and  non-speciﬁc  retinal  detachment.  The  most  concerning
of  these  are  choroidal  melanoma  and  choroidal  metastasis
because  of  their  risk  of  ocular  and  systemic  morbidity  and
mortality.3
Patients  with  central  serous  chorioretinopathy  are  typ-
ically  middle-aged  adults  who  present  with  complaints  of
decreased  vision.  Examination  reveals  an  elevated  area  in
the  macula,  usually  with  associated  subretinal  ﬂuid.  It  is
typically  the  same  color  as  the  surrounding  retina.  This
condition  is  benign  and  often  resolves  without  treatment,
although  recurrence  is  possible.2
Posterior  nodular  scleritis  can  present  as  a  tumor-like
mass  in  the  posterior  pole.  This  can  be  distinguished  from
CCH  because  other  signs  and  symptoms  of  ocular  inﬂamma-
tion,  such  as  vitreous  cells  or  anterior  scleritis,  are  usually
present.10
Choroidal  metastases  often  present  as  elevated,  plateau-
shaped  lesions.  They  can  be  found  anywhere  in  the  posterior
segment  of  the  eye,  including  the  posterior  pole,  and  are
typically  a  creamy  yellow  color.  Unlike  CCH,  they  can  be
multifocal  or  bilateral.2,3
Choroidal  melanoma  is  typically  a  large  mushroom-
shaped,  pigmented  lesion  that  can  be  found  anywhere  in
the  posterior  segment  of  the  eye.  Masses  larger  than  2  mm
are  considered  suspicious  for  melanoma.  However,  most
measure  greater  than  10  mm  at  diagnosis.  The  majority  of
melanomas  are  darkly  pigmented  with  either  a  black  or  gray-Please  cite  this  article  in  press  as:  Berry  M,  Lucas  LJH.  Circumsc
review.  J  Optom.  (2016),  http://dx.doi.org/10.1016/j.optom.2
green  appearance,  but  amelanotic  melanomas  also  exist.2
This  lesion  can  be  confused  with  a  CCH,  but  its  appearance
is  somewhat  different  since  it  is  yellow  to  tan  in  color  and
sometimes  has  overlying  drusen.3
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It  is  important  to  be  able  to  differentiate  between  differ-
nt  types  of  ocular  tumors  in  order  to  provide  appropriate
reatment.  As  mentioned  previously,  some  conditions  such
s  choroidal  melanoma  require  correct  diagnosis  and  prompt
reatment  to  reduce  the  risk  of  ocular  and  systemic  morbid-
ty  and  mortality.
ncillary  testing
ince  CCH  can  mimic  several  other  ocular  conditions,  addi-
ional  testing  is  required  for  proper  diagnosis.  These  tests
nclude  ultrasonography,  FA,  ICGA,  MRI,  and  OCT.2,3,12,13
Ultrasonography  can  be  used  to  measure  the  internal
eﬂectivity  of  an  ocular  mass.  High  internal  reﬂectivity  on  A-
can,  or  acoustically  solid  on  B-scan,  indicates  that  the  mass
s  composed  of  a  variety  of  different  cell  types,  which  causes
ore  disruption  of  the  sound  waves.  Normal  choroidal  tissue
s  made  of  several  different  cell  types.  Low  internal  reﬂec-
ivity  on  A-scan,  or  acoustic  hollowness  on  B-scan,  is  a  sign
hat  very  similar  cells  are  located  within  the  lesion.  CCH  is
haracterized  by  high  internal  reﬂectivity  since  it  is  com-
osed  of  blood  vessels  and  other  cells  that  are  similar  to  the
ormal  choroidal  structure.3 This  is  in  contrast  to  choroidal
elanomas,  which  usually  show  acoustic  hollowness  and  low
o  medium  internal  reﬂectivity.  On  the  other  hand,  choroidal
etastasis  shows  similar  ﬁndings  to  CCH  and  is  not  as  easily
istinguished  from  CCH  with  ultrasonography.2,3
FA  allows  viewing  of  the  retinal  blood  vessels  and  is
ften  used  to  locate  areas  of  leakage.  CCH  shows  a  char-
cteristic  pattern  on  FA  which  includes  mild  early  lacy
yperﬂourescence  that  increases  through  all  stages.  In  con-
rast,  choroidal  melanoma  and  choroidal  metastasis  show
lower  and  less  intense  hyperﬂourescence.2,3 Central  serous
horioretinopathy,  on  the  other  hand,  shows  early  hypoﬂu-
rescence  followed  by  the  classic  smoke  stack  appearance
f  ﬂuid  leakage.
ICGA  gives  similar  data  to  FA,  but  ICGA  allows  visualiza-
ion  of  the  choroidal  vasculature  as  opposed  to  the  overlying
etinal  vessels.  CCH  characteristically  shows  extreme  hyper-
ourescence  in  the  early  stages  which  decreases  in  the
ate  stages,  also  known  as  the  ‘‘wash-out’’  phenomenon.  In
ontrast,  choroidal  melanoma  and  metastasis  demonstrate
lower  and  less  intense  ﬁlling.2,3
MRI  can  be  used  to  locate  lesions  within  the  orbit.
nfortunately,  both  CCH  and  choroidal  melanomas  show
imilar  characteristics  on  MRI.  Both  are  hyperintense  on
1-weighted  images.  On  T2-weighted  images,  both  are  isoin-
ense  compared  to  the  vitreous  and  tend  to  disappear  on  the
mage.3 Although  MRI  does  allow  visualization  of  the  loca-
ion  of  the  mass,  it  is  not  a  very  useful  test  for  helping  to
ifferentiate  CCH  from  choroidal  melanoma.2
If  all  other  testing  is  inconclusive,  a  biopsy  of  the  lesion
an  be  performed.  This  is  a  more  invasive  procedure  and
herefore  carries  greater  risks.  It  is  usually  reserved  for
ases  where  the  diagnosis  cannot  be  made  with  less  involved
ethods.3
OCT  is  a  newer  technology  which  shows  high  deﬁni-ribed  choroidal  hemangioma:  A  case  report  and  literature
015.12.006
ion  imaging  of  the  posterior  segment  of  the  eye.  It  is
specially  helpful  in  detecting  lesions  which  are  less  than
 mm  thick.  Clinically,  it  is  used  most  often  to  monitor  for
omplications  of  CCH  such  as  macular  edema  and  serous
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etinal  detachment.  It  can  also  be  used  to  evaluate  the
fﬁcacy  of  treatment.2,13
reatment  options
CH  is  often  an  asymptomatic  lesion.  In  this  case,  close
bservation  is  the  only  treatment  warranted.  Although  the
esion  itself  is  benign,  it  can  lead  to  sight-threatening
omplications,  including  macular  edema,  serous  retinal
etachment,  or  neovascular  glaucoma.  The  most  common
ymptom  in  patients  with  CCH  is  blurred  vision  secondary  to
acular  edema.  If  complications  do  arise,  there  are  several
reatment  options  available.  The  goal  of  any  treatment  is
esolution  of  the  macular  edema.3 Any  decrease  in  tumor
ize  is  a  beneﬁt  but  is  not  the  primary  purpose  of  the
reatment.11
In  the  1960s  and  1970s,  the  traditional  treatment  for  CCH
as  xenon  arc  photocoagulation.  This  was  performed  over
he  entire  surface  of  the  tumor.  It  produced  good  resolution
f  subretinal  ﬂuid  but  often  left  residual  scarring  that  could
imit  the  patient’s  visual  recovery.9,12 After  the  1970s,  the
rgon  laser  became  the  preferred  laser  for  photocoagulation
f  CCH.  Argon  laser  can  also  cause  scarring  of  the  choroid
nd  retina,  however,  which  can  lead  to  decreased  visual  acu-
ty.  Re-treatments  are  often  necessary  as  subretinal  ﬂuid
ends  to  recur.  Photocoagulation  can  sometimes  lead  to  sig-
iﬁcant,  if  not  complete,  resolution  of  subretinal  ﬂuid  but
ypically  has  a  little  to  no  effect  on  the  tumor  size.1,3,9,12
ost  patients’  visual  acuity  remains  stable  or  improves  after
reatment.  This  success  rate,  along  with  its  wide  availability
nd  cost-effectiveness,  makes  argon  laser  photocoagulation
 reasonable  treatment  choice  for  many  patients.1,3
Another  treatment  available  for  CCH  is  transpupillary
hermotherapy  (TTT),  where  a  diode  laser  with  a broad
eam  and  long  exposure  time  is  used  to  treat  the  lesion.  This
aser  penetrates  deeper,  causing  hyperthermia  and  occlu-
ion  of  blood  vessels  with  less  damage  to  the  surrounding
etina.  This  leads  to  a  decrease  in  subretinal  ﬂuid  as  well  as
 decrease  in  overall  tumor  size.  Since  this  therapy  pene-
rates  deeper,  it  can  lead  to  damage  of  the  retinal  pigment
pithelium.  Complications  include  branch  retinal  vein  occlu-
ion,  recurrent  macular  edema,  scarring,  and  pre-retinal
brosis.  If  macular  edema  recurs,  the  treatment  can  be
epeated  every  two  to  three  months.  However,  the  risk
f  complication  increases  with  every  re-treatment.2,3,9 For
his  reason,  TTT  is  usually  reserved  for  lesions  less  than
0  mm  in  diameter,  less  than  4  mm  in  thickness,  and  more
han  3  mm  from  the  foveola.  TTT  is  also  not  effective  for
esions  with  large  amounts  of  overlying  ﬂuid  or  large  retinal
etachments.3,9
Since  the  late  1980s,  radiation  therapy  has  been  available
or  the  treatment  of  CCH.  The  three  most  common  types
f  radiation  therapy  include  episcleral  plaque  radiotherapy,
xternal  beam  irradiation,  and  proton  beam  irradiation.
adiation  therapy  is  usually  used  in  cases  of  CCH  where  pho-
ocoagulation  cannot  be  applied,  such  as  for  large  extensive
etinal  detachments  or  subfoveal  lesions.  Episcleral  plaquePlease  cite  this  article  in  press  as:  Berry  M,  Lucas  LJH.  Circumsc
review.  J  Optom.  (2016),  http://dx.doi.org/10.1016/j.optom.
adiotherapy,  or  brachytherapy,  is  the  process  of  placing  a
adioactive  plaque  under  the  tumor.2,3,9 The  plaque  is  sur-
ically  attached  to  the  episclera  then  left  in  place  until  the
esired  amount  of  radiation  is  delivered.  Later,  a  second
p
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urgical  procedure  is  performed  to  remove  the  plaque.  The
adiation  therapy  results  in  a  decrease  of  subretinal  ﬂuid
ause  by  shrinkage  of  the  tumor  itself.  The  success  rate  is
ery  high  for  this  treatment,  even  in  eyes  in  which  previous
reatments  have  failed.3,9 Another  form  of  radiation  therapy
hat  has  been  employed  for  treatment  of  CCH  is  external
eam  radiotherapy.  This  technique  is  often  used  for  diffuse
horoidal  hemangiomas  but  can  be  used  for  CCH  as  well.13
t  is  used  as  a  stand-alone  treatment  or  in  conjunction  with
ther  treatments  such  as  argon  laser  photocoagulation.  One
ossible  complication  of  this  treatment  is  cataracts,  so  a
ens-sparing  technique  is  often  used.1,3,9 The  newest  form
f  radiation  therapy  is  proton  beam  radiotherapy,  treatment
hat  uses  charged  particles  which  are  slowed  down  at  the
umor  site.  This  allows  a  homogeneous  dose  of  radiation  at
he  tumor  while  sparing  the  surrounding  tissues.  Like  other
adiotherapies,  proton  beam  radiation  causes  a  decrease  in
umor  size  and  subsequent  resolution  of  subretinal  ﬂuid.  This
rocedure,  however,  is  very  expensive  and  has  very  limited
vailability.7,9 Generally,  the  radiation  therapy  of  choice  is
piscleral  plaque  radiotherapy.  This  method  allows  the  radi-
tion  to  be  placed  at  the  base  of  the  tumor  right  under
he  blood  supply.  It  also  takes  less  time,  typically  requir-
ng  only  2--4  days  of  therapy  before  removal  of  the  plaque.
his  type  of  procedure  also  decreases  the  amount  of  ante-
ior  segment  damage  from  radiation.  The  main  drawback  to
his  method  is  that  it  requires  two  separate  surgical  proce-
ures  to  place  and  later  remove  the  plaque.2,3,9 All  types
f  radiation  therapies  carry  some  risk  of  complications  from
he  radiation.  These  include  cataracts,  radiation  retinopa-
hy,  dry  eye,  and  neovascular  glaucoma.2 For  this  reason,
adiotherapy  is  rarely  chosen  as  a  ﬁrst-line  therapy  for  CCH.
PDT  has  been  shown  to  be  a  safe  and  effective  treatment
or  CCH.  PDT  uses  a  photochemical  to  selectively  occlude
ascular  channels  in  the  CCH.  The  photochemical  binds  to
ow  density  lipoproteins  which  are  present  in  large  amounts
n  the  tumor’s  endothelium.  Following  the  injection  of  the
hotochemical,  a  laser  is  applied,  and  this  causes  a  reac-
ion  only  in  areas  that  are  bound  to  the  photochemical.  The
bjective  is  to  allow  very  speciﬁc  treatment  with  minimal
amage  to  surrounding  tissue.5,9 Since  the  most  common
ymptom  in  patients  with  CCH  is  blurred  vision  due  to  serous
etinal  detachment  involving  the  macula  or  macular  edema,
he  goal  of  treatment  is  resolution  of  the  macular  edema  and
ubretinal  ﬂuid.  Some  patients  who  undergo  PDT  also  show
 regression  in  tumor  size  as  well.  One  possible  side  effect  is
horoidal  atrophy  from  repeated  treatments.  Overall,  PDT
s  a  safe  and  effective  primary  or  secondary  treatment  for
CH.5,14,15
Intravitreal  injection  of  anti-VEGF  medication  has  been
 frequently  used  treatment  for  wet  macular  degeneration
nd  diabetic  macular  edema  for  several  years.  Recently,  it
as  also  been  used  to  help  treat  macular  edema  secondary
o  CCH.  This  treatment  is  minimally  invasive  and  has  a  lit-
le  to  no  effect  on  the  surrounding  retinal  tissue.  Anti-VEGF
edication  has  been  shown  to  be  effective  in  resolving  mac-
lar  edema  in  some  patients  with  CCH.  One  drawback  to
his  treatment  is  that  it  needs  to  be  repeated  often.  Mostribed  choroidal  hemangioma:  A  case  report  and  literature
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atients  had  return  of  some  macular  edema  three  to  six
onths  after  treatment.  Its  relative  lack  of  efﬁcacy  may
e  due  to  the  nature  of  the  mature  vessels  composing  the
emangioma,  as  opposed  to  neovascular  vessels  or  vessels
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that  have  been  compromised  by  diabetic  disease.  Due  to
its  short-term  effect,  this  treatment  is  often  combined  with
other  previously  mentioned  therapies  for  CCH.7,9,16
Enucleation  is  a  last  resort  treatment  for  CCH.  Most  eyes
that  undergo  enucleation  are  result  of  the  misdiagnosis  of
a  choroidal  melanoma.7,13 This  underscores  the  importance
of  ancillary  testing  and  proper  diagnosis.  Other  reasons
for  enucleation  include  a  total  retinal  detachment  or
development  of  neovascular  glaucoma  resulting  in  a blind
painful  eye.7,13
Conclusion
Although  CCH  is  a  rare  retinal  ﬁnding,  it  is  important  to  be
able  to  distinguish  it  from  other  similar  retinal  tumors.7,13
Clinical  presentation  as  well  as  the  use  of  ancillary  test-
ing  can  be  used  to  properly  diagnose  this  condition.  These
tests  include  ultrasonography  (A/B  scan),  FA,  ICGA,  MRI,
and  OCT.1,3,6,7 CCH  is  difﬁcult  to  diagnosis  in  some  cases
because  it  mimics  several  other  posterior  segment  ﬁndings.
Prompt  diagnosis  to  a  retinal  specialist  is  necessary  if  any
uncertainty  exists.7 Treatment  is  only  indicated  for  CCH
when  subretinal  ﬂuid  affects  the  macular  area  and  causes
decreased  vision  for  the  patient.  When  macular  subretinal
ﬂuid  or  macular  edema  is  present,  a  retinal  specialist  can
then  make  the  decision  of  which  treatment  option  to  use
based  on  several  factors,  including  tumor  size  and  location,
as  well  as  characteristics  of  the  subretinal  ﬂuid.7,13 Despite
its  status  as  a  benign  tumor,  CCH  can  lead  to  profound  vision
loss  in  about  half  of  all  cases  secondary  to  long-term  mac-
ular  edema.12 The  earlier  that  treatment  is  implemented,
the  better  the  visual  outcome  for  the  patient.13 Several
treatment  options  are  available  presently,  including  argon
laser  photocoagulation,  episcleral  plaque  radiation  ther-
apy,  external  beam  radiotherapy,  proton  beam  radiotherapy,
TTT,  PDT,  and  intravitreal  anti-VEGF  therapy.2--4,6,8,9,11--15
Enucleation  is  reserved  for  blind  painful  eyes  after  other
therapies  have  failed.  Treatment  options  continue  to  evolve.
Long-term  studies  are  difﬁcult  to  conduct  on  such  an  uncom-
mon  condition,  but  would  be  useful  in  guiding  treatment  for
patients  with  CCH.
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